A 58-year-old woman with newly diagnosed multiple myeloma (IgG-κ type, standard-risk cytogenetics, creatinine 1.2 mg/dL, hemoglobin 10.5 g/dL) has completed 4 cycles of bortezomib-lenalidomide-dexamethasone (VRd) induction. Serum M-protein has decreased from 3.8 g/dL to 0.6 g/dL, and bone marrow plasma cells have dropped from 65% to 8%. She is medically fit. What is the most appropriate next step in management?

Question

Accepted Answer

C. Proceed to autologous stem cell transplantation (ASCT) after mobilization. ## Autologous Stem Cell Transplantation in Standard-Risk MM **Key Point:** In newly diagnosed multiple myeloma (NDMM) with standard-risk cytogenetics, **autologous stem cell transplantation (ASCT) after 4–6 cycles of induction therapy is the standard of care** for transplant-eligible patients. ### Rationale for ASCT in This Patient **High-Yield:** ASCT improves **progression-free survival (PFS)** and **overall survival (OS)** in NDMM compared to chemotherapy alone, regardless of response depth after induction. **Clinical Pearl:** The goal of induction is NOT to achieve complete remission (CR) before transplant — it is to: 1. Reduce tumor burden 2. Assess chemosensitivity 3. Mobilize stem cells 4. Prepare the patient medically This patient shows **excellent response** (M-protein 3.8 → 0.6 g/dL, BM plasma cells 65% → 8%), confirming chemosensitivity and suitability for ASCT. ### Treatment Algorithm for Standard-Risk NDMM ```mermaid flowchart TD A[NDMM diagnosed
Standard-risk cytogenetics]:::outcome --> B[Induction: PI + IMiD ± corticosteroid
4-6 cycles]:::action B --> C{Transplant eligible?}:::decision C -->|Yes| D[Stem cell mobilization]:::action D --> E[ASCT]:::action E --> F[Consolidation ± maintenance]:::action C -->|No| G[Continuous therapy
or observation]:::action F --> H[Long-term follow-up]:::outcome ``` ### Why Proceeding to ASCT is Correct | Factor | Evidence | |--------|----------| | **Transplant eligibility** | Age 58, fit, no major comorbidities ✓ | | **Induction cycles** | 4 cycles completed (standard is 4–6) ✓ | | **Response achieved** | Excellent response (M-protein ↓ 84%, BM plasma cells ↓ 87%) ✓ | | **Standard of care** | ASCT improves PFS/OS in standard-risk NDMM ✓ | | **Timing** | Proceed after induction, not after CR ✓ | **Mnemonic — ASCT Eligibility Criteria:** **A**ge <75 (usually), **S**ufficient **C**ardiopulmonary **T**oleration, no major organ dysfunction, fit performance status. ### Why Other Options Are Incorrect **Option A (Continue VRd 2 more cycles):** - Prolonging induction beyond 4–6 cycles does NOT improve outcomes and delays transplant. - Response is already excellent; further induction is unnecessary and may increase toxicity. **Option C (Maintenance lenalidomide):** - Maintenance is given **after** ASCT, not instead of it. - Skipping ASCT in a transplant-eligible patient with standard-risk disease is suboptimal. **Option D (Repeat bone marrow biopsy for CR confirmation):** - Bone marrow biopsy is not required to proceed to ASCT. - Response assessment by serum/urine M-protein and imaging is sufficient. - Delaying ASCT for confirmatory biopsy is unnecessary and reduces benefit. [cite:Harrison 21e Ch 186; NCCN Multiple Myeloma Guidelines 2023]

Answer

A. Switch to maintenance therapy with lenalidomide monotherapy

Answer

B. Perform repeat bone marrow biopsy to confirm complete remission before further treatment

Answer

D. Continue VRd for 2 more cycles, then reassess

Explanation

Autologous Stem Cell Transplantation in Standard-Risk MM

Rationale for ASCT in This Patient

Treatment Algorithm for Standard-Risk NDMM

Why Proceeding to ASCT is Correct

Why Other Options Are Incorrect

Practice similar questions

Join our NEET PG community

Factor	Evidence
Transplant eligibility	Age 58, fit, no major comorbidities ✓
Induction cycles	4 cycles completed (standard is 4–6) ✓
Response achieved	Excellent response (M-protein ↓ 84%, BM plasma cells ↓ 87%) ✓
Standard of care	ASCT improves PFS/OS in standard-risk NDMM ✓
Timing	Proceed after induction, not after CR ✓